The role of botulinum toxin type B (Myobloc) in the treatment of hyperkinetic facial lines.
Botulinum toxin type B was studied for the management of hyperkinetic facial lines. It showed clinical longevity of up to 12 weeks on subjective rating scales and 8 weeks on objective rating scales. Botulinum toxin type B has shown relative safety but can have autonomic side effects at higher total doses, which limits the possibility of continued dose escalation. Although these findings may preclude its use as a primary modality for the use in hyperkinetic facial lines, botulinum toxin type B still has a role in the treatment of the aesthetic patient and is yet another tool in the armamentarium of aesthetic practitioners.
D001905:Botulinum Toxins / Q000494:pharmacology*; D019274:Botulinum Toxins, Type A; D003357:Cosmetic Techniques; D005145:Face; D005260:Female; D006801:Humans; D006948:Hyperkinesis / Q000188:drug therapy; D008297:Male; D010865:Pilot Projects; D015595:Skin Aging / Q000187:drug effects*
C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A